Immunogen providing an extended protective lifetime against respiratory syncytial virus (RSV) and vaccines thereof
AssigneeTrellis Bioscience, LLC
InventorsMilton J. Friedman, Lawrence M. Kauvar
Life of this patent
Estimating the term…
Abstract
Improvements to vaccines against RSV include G protein CCD portions complexed with mAb that block interaction with CX3C-R and modified forms of mAb to prolong serum half-life, as well as inhalable vaccines.
Claims17
An immunogen providing an extended protective lifetime against respiratory syncytial virus (RSV) comprising a complex formed by an RSV G protein or peptidomimetic, wherein said RSV G protein includes a central conserved domain (CCD) with a monoclonal antibody or antigen-binding fragment thereof that blocks interaction of the recombinant RSV G protein with host receptor CX3CR1.
An immunogen against respiratory syncytial virus (RSV) comprising a complex formed by an RSV G protein or peptidomimetic, wherein said RSV G protein includes a central conserved domain (CCD), wherein the CCD comprises residues selected from the group consisting of residues 131-230 and residues 167-176 of said RSV G protein with a monoclonal antibody or antigen-binding fragment thereof that blocks interaction of the recombinant RSV G protein with host receptor CX3CR1, wherein the monoclonal antibody or fragment has an affinity with a Kd of less than about 1 nM, and wherein said immunogen is for inhalation.
Dependencies are inferred from the claim text.